Sleep Health, Inflammation, and Emotion Study



Status:Recruiting
Conditions:Depression
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:60 - 80
Updated:10/18/2018
Start Date:October 2014
End Date:January 2020
Contact:Hyong Jin Cho, MD, PhD
Email:hjcho@mednet.ucla.edu
Phone:310-825-8425

Use our guide to learn which trials are right for you!

Sleep Loss as a Vulnerability Factor for Inflammation Induced Depressive Symptoms in Older Women

Late-life depression is a major public health burden due to its high prevalence and
associated morbidity, suicide risk, functional decline, and mortality. Unfortunately, current
antidepressant therapies have limited effectiveness; hence, biologically plausible models for
new treatments are being pursued. Systemic inflammation is hypothesized to play an important
role on the onset and perpetuation of depression, especially in older women. Aging processes
involve a heightened inflammatory state, and both inflammatory disorders and depression are
more prevalent in women than men. However, increased systemic inflammation does not
necessarily lead to depression in all women. Even when robust systemic inflammation is
experimentally induced (e.g. endotoxin administration), largely variable increases in
depressive symptoms are found. Defining the factors that account for this variability may
identify individuals at risk of developing depression when exposed to heightened inflammatory
states such as aging, obesity, and chronic disease, and informs future translational studies
of depression prevention. In particular, the role of sleep disturbance in explaining this
variability requires further attention because it is an independent risk factor for
depression and heightens systemic inflammation by increasing the production of
proinflammatory cytokines. The investigators have also discovered that women, but not men,
who report sleep disturbance including short sleep duration experience significantly more
depressive symptoms in response to an inflammatory challenge than women without sleep
disturbance. Thus, it is hypothesized that sleep loss is a vulnerability factor for
inflammation-induced depressive symptoms in women. However, to date, no experimental approach
has been used to evaluate the role of sleep loss on inflammation-induced depressive symptoms.
This proposal aims to examine this hypothesis by partial sleep deprivation (PSD) followed by
endotoxin challenge in older women. It also aims to explore genomic and socio- emotional
mechanisms underlying the association between sleep loss and depressive symptoms. In a
randomized controlled factorial design, 80 healthy female volunteers aged 60 to 80 will be
randomly assigned to one of 4 arms: 1) uninterrupted sleep followed by placebo; 2)
uninterrupted sleep followed by endotoxin; 3) PSD followed by placebo; or 4) PSD followed by
endotoxin. Subjects will be administered placebo or endotoxin in the morning after PSD or
uninterrupted sleep. Depressive symptoms will be repeatedly assessed over 6 hours after
placebo or endotoxin administration.


Inclusion Criteria:

- to be in good general health

- to be female

- to be aged 60 to 80 years

Exclusion Criteria:

- presence of chronic mental or physical illnesses

- history of allergies, auto-immune, liver, or other chronic diseases

- current use of prescription medications such as steroids, non-steroid
anti-inflammatory drugs, immune modifying drugs, opioid analgesics, and psychotropic
medications

- current sleep disorders such as insomnia or sleep apnea

- nightshift work or time zone shifts (> 3 hours) within the previous 6 weeks

- an Axis I psychiatric disorder as determined by the Research Version of the Structured
Clinical Interview for DSM-5 (SCID-5-RV) including a current or within 1 year
prior-to-study history of major depressive disorder (a history of depression 1 or more
years prior to the study is not an exclusion criterion, which will be considered for a
pre-planned sensitivity analysis, however, any prior depressive episode severe enough
to have involved suicidal ideation or required an inpatient psychiatric admission is
an exclusion criterion)

- prior or current suicidal ideation assessed by the Columbia Suicide Severity Rating
Scale (C-SSRS)

- current depressive symptoms assessed by the Patient Health Questionnaire (PHQ-9) (≥ 5)

- sleep disorders identified by the SCID and the Duke Structured Interview for Sleep
Disorders (DSISD)

- sleep disturbance defined by the Pittsburgh Sleep Quality Index (PSQI) (≥ 5)

- a positive screen for sleep apnea using the Berlin Sleep Apnea Questionnaire

- excessive caffeine use (>600 mg/day)

- BMI > 35 due to the effects of obesity on cytokine activity and risk for sleep
disordered breathing

- evidence of recreational drug use from urine test

- any abnormalities on screening laboratory tests.
We found this trial at
1
site
Los Angeles, California 91744
Phone: 310-825-8425
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials